Combining options in metastatic prostate cancer

Ryan Kopp; Tomasz (Tom) Beer

doi:10.1038/s41585-019-0217-z

Combining options in metastatic prostate cancer

Ryan Kopp, Tomasz (Tom) Beer

School of Nursing

Research output: Contribution to journal › Comment/debate

Abstract

Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

Original language	English (US)
Journal	Nature Reviews Urology
DOIs	https://doi.org/10.1038/s41585-019-0217-z
State	Published - Jan 1 2019

ASJC Scopus subject areas

Urology

Access to Document

10.1038/s41585-019-0217-z

Fingerprint Dive into the research topics of 'Combining options in metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this

Kopp, R., & Beer, T. T. (2019). Combining options in metastatic prostate cancer. Nature Reviews Urology. https://doi.org/10.1038/s41585-019-0217-z

@article{9bfd93261ace48bfa1c1886014406b08,

title = "Combining options in metastatic prostate cancer",

abstract = "Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.",

author = "Ryan Kopp and Beer, {Tomasz (Tom)}",

year = "2019",

month = jan,

day = "1",

doi = "10.1038/s41585-019-0217-z",

language = "English (US)",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Combining options in metastatic prostate cancer

AU - Kopp, Ryan

AU - Beer, Tomasz (Tom)

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

AB - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

UR - http://www.scopus.com/inward/record.url?scp=85069468976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069468976&partnerID=8YFLogxK

U2 - 10.1038/s41585-019-0217-z

DO - 10.1038/s41585-019-0217-z

M3 - Comment/debate

C2 - 31320748

AN - SCOPUS:85069468976

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

ER -